Imagine surviving thyroid cancer, only to face a new battle for your health and quality of life. This is the harsh reality for thousands of Australians living with chronic hypoparathyroidism, a condition often triggered by thyroid cancer treatment. Despite the existence of a TGA-approved drug called Yorvipath, which could prevent kidney failure and other debilitating complications, these survivors are left in limbo, unable to access this potentially life-changing treatment.
Yorvipath, approved by the Therapeutic Goods Administration (TGA) in February 2025, offers hope by replacing the missing hormone in chronic hypoparathyroidism. However, the Pharmaceutical Benefits Advisory Committee (PBAC) has rejected its listing on the Pharmaceutical Benefits Scheme (PBS) twice, citing concerns over its price. But here's where it gets controversial: while the PBAC acknowledges Yorvipath’s superior effectiveness compared to conventional therapy, they argue the proposed cost doesn’t align with its long-term benefits. This leaves patients trapped in a Catch-22—without access to the drug, there’s no real-world data to prove its long-term value, yet without that data, approval remains elusive.
And this is the part most people miss: the current standard treatment, high-dose calcium and vitamin D, often leads to severe side effects like kidney damage, unstable calcium levels, fatigue, cognitive issues, and cardiovascular strain. For survivors like Hannah Nyx, a WA-based counsellor and art therapist who developed hypoparathyroidism after thyroid cancer surgery, this means a daily struggle to manage her health while trying to maintain her business. “I didn’t really know about this condition before having it,” Hannah shares. “Now, I’m at high risk of kidney failure and heart issues, and I can’t access the drug that could prevent this.”
Hannah’s story is far from unique. A petition she started to provide access to Yorvipath has garnered over 450 signatures, highlighting the urgency of this issue. Her friend and colleague, Dr. John Forbes, an endorsed clinical psychologist, emphasizes the absurdity of the situation: “It’s almost impossible for her to function some days. The government is blocking a preventative therapy that costs a fraction of the dialysis it would ultimately avoid.”
Here’s the kicker: countries like Germany, Japan, and the US have already resolved this issue, yet Australia lags behind. The Department of Health, Disability and Ageing points to the PBAC’s role in advising on subsidized medicines, but the question remains: at what cost are we delaying access to life-improving treatments?
What do you think? Is the PBAC’s focus on cost-effectiveness overshadowing the immediate needs of patients? Should Australia prioritize access to Yorvipath, even if it means renegotiating its price? Share your thoughts in the comments—this is a conversation that needs to happen.
